The shingles vaccine: Why hasn’t it caught on?
The shingles vaccine Zostavax has not turned out to be as popular as was expected, due in part to its high cost and questions about its effectiveness.
Content restricted. Requires subscription
The shingles vaccine Zostavax has not turned out to be as popular as was expected, due in part to its high cost and questions about its effectiveness.